Pharmaxis has a strong suite of products in development, primarily focused on treating respiratory diseases. The target disease states are under-treated and many have broad patient bases.



Pharmaxis' first commercial product, the innovative Aridol lung function test, is designed to assist physicians in the overall assessment of asthma by identifying and measuring airway hyperresponsiveness.

By having patients inhale Aridol via a simple hand-held device, doctors can determine the severity of a patient's inflammation and prescribe the right amount of medication to bring it under control. The Aridol challenge test potentially prevents inappropriate treatment and may help patients better comply with their therapies.

Aridol is approved for sale in Australia, major European countries, South Korea and the United States.




Pharmaxis' key product is Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions.

Pharmaxis developed Bronchitol for diseases including bronchiectasis, cystic fibrosis and chronic bronchitis. Bronchitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively. Clinical studies have shown Bronchitol to be effective and well tolerated, to improve quality of life and mucus flow in people with cystic fibrosis and bronchiectasis.

Bronchitol is an Australian discovered and developed product which was approved for marketing in Australia in February 2011. In April 2012 Bronchitol was approved for marketing in the European Union by the European Medicines Agency.